Dare Bioscience, Inc. (NASDAQ:DARE) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET
Company Participants
Sabrina Johnson - President and Chief Executive Officer
Lisa Walters-Hoffert - Chief Financial Officer
John Fair - Chief Strategy Officer
Conference Call Participants
Kumaraguru Raja - ROTH Capital
Operator
Welcome to the conference call hosted by Dare Bioscience to review the company's financial results for the quarter ended September 30, 2022 and to provide a general business update. This call is being recorded. My name is Paula and I will be your operator today. With us today are Sabrina Martucci Johnson, Dare's President and Chief Executive Officer; John Fair, Dare's Chief Strategy Officer; and Lisa Walters-Hoffert, Dare's Chief Financial Officer.
Ms. Johnson, please proceed.
Sabrina Johnson
Thank you. Good afternoon, and welcome to our Third Quarter 2022 Financial Results and Business Update Call for Dare Bioscience. Our plan today is to review our third quarter results, discuss development since our last call in August and use the time to review our business strategy including why we believe investment in women's health is efficient and disproportionately impactful and to highlight some important objectives and milestones anticipated through the end of the year and in 2023.
Before we begin, I'd like to remind you that today's discussion will include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts should be considered forward-looking statements. Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties. You should not place undue reliance on forward-looking statements.
Forward-looking statements are qualified in their entirety by the cautionary statements in the company's SEC filings, including our annual report on Form 10-K for the year ended December 31, 2021, which was filed on March 31, 2022, and our quarterly report on Form 10-Q for the quarter ended June 30, 2022, which was filed today. I would also like to point out that the content of this call includes time-sensitive information that is current only as of today, November 10, 2022. Dare undertakes no obligation to update any forward-looking statements to reflect new information or developments after this call, except as required by law.
As you know, Dare is solely and squarely focused in women's health. It is our belief that prioritizing women's health is not only good for the many women lacking effective or convenient therapeutic choices, but also for a broad set of stakeholders, including their families and partners and, of course, our shareholders.